NASDAQ · ORMP
Oramed Pharmaceuticals Inc.
$4.11-$0.12 (-2.84%)
Oramed Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.86% below the high.
Loading market information…
OTC · NBRVF · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Nabriva Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Nabriva Therapeutics plc’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$16.75. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nabriva Therapeutics plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nabriva Therapeutics plc is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative anti-infective medicines for managing serious infections. Its current portfolio includes SIVEXTRO, an oxazolidinone-class antibacterial utilized for acute bacterial skin and skin structure infections (ABSSSI). Another key product is XENLETA, a semi-synthetic pleuromutilin antibiotic available for both oral and intravenous administration. XENLETA is also currently advancing through Phase I clinical trials for additional indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Moreover, the company is progressing CONTEPO, an epoxide antibiotic designed to address complicated urinary tract infections, which is concurrently in Phase I clinical evaluation for peri-operative prophylaxis. Founded in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and is headquartered in Dublin, Ireland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:15 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$4.11-$0.12 (-2.84%)
Oramed Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.86% below the high.
CA$0.05CA$0.00 (0.0%)
MedMira Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.38% below the high.
$0.86-$0.05 (-5.35%)
Brainstorm Cell Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.11% below the high.
$2.05-$0.32 (-13.5%)
Jupiter Neurosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.13% below the high.
$0.18+$0.04 (+28.57%)
Hepion Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.18% below the high.
$0.66-$0.02 (-3.45%)
Creative Medical Technology Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.12% below the high.
$0.01-$0.00 (-2.44%)
Evofem Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.14% below the high.
$0.00$0.00 (0.0%)
G Medical Innovations Holdings Ltd’s quoted price sits in the lower half of its reported 52-week range, 99.6% below the high.
